StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)

Stock analysts at StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a note issued to investors on Tuesday. The firm set a “sell” rating on the stock.

Oragenics Trading Up 3.7 %

OGEN stock opened at $0.28 on Tuesday. The business’s 50-day moving average price is $0.31 and its two-hundred day moving average price is $0.41. The firm has a market cap of $3.42 million, a PE ratio of -0.04 and a beta of 0.85. Oragenics has a 1-year low of $0.25 and a 1-year high of $3.43.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.